Our work pioneers the identification of MGLL as a regulator of endothelial senescence and a direct molecular target of TZ, thereby expanding TZ’s therapeutic scope beyond BPH to vascular and metabolic aging. This evidence concerns the gene MGLL and benign prostatic hyperplasia.